A One-Year, Multicenter, Observational, Follow-up Safety Study in Subjects Previously Implanted With VC-01™ Combination Product
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors ViaCyte
- 03 Nov 2017 Planned End Date changed from 1 Nov 2023 to 1 Nov 2021.
- 03 Nov 2017 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2021.
- 21 Oct 2016 New trial record